Drug profile · INN
fosfomycin tromethamine
FOSFOMYCIN TROMETHAMINE
fosfomycin tromethamine (FOSFOMYCIN TROMETHAMINE) is a udp-n-acetylglucosamine 1-carboxyvinyltransferase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — fosfomycin tromethamine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
fosfomycin tromethamine (FOSFOMYCIN TROMETHAMINE) is a udp-n-acetylglucosamine 1-carboxyvinyltransferase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor
Primary target: UDP-N-acetylglucosamine 1-carboxyvinyltransferase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Frequently asked questions
What is fosfomycin tromethamine?
fosfomycin tromethamine (FOSFOMYCIN TROMETHAMINE) is a udp-n-acetylglucosamine 1-carboxyvinyltransferase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for fosfomycin tromethamine?
FOSFOMYCIN TROMETHAMINE is a marketed brand name for fosfomycin tromethamine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of fosfomycin tromethamine?
fosfomycin tromethamine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.